Bristol Myers Squibb Company gained a nearly $16bn hematology franchise through its acquisition of Celgene Corporation in late 2019, but three-fourths of that new revenue will start to disappear next year as generic versions of top-selling drug Revlimid (lenalidomide) begin to launch in 2022. However, BMS has a plan to maintain and build upon its hematology legacy and will unveil data underlying some elements of that strategy during the 11-14 December American Society of Hematology (ASH) meeting.
Bristol’s hematology drug sales totaled $18.13bn in 2020 – including $2.14bn from Sprycel (dasatinib) and $381m from Empliciti (elotuzumab), the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?